Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have received an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $15.63 for the company and are anticipating that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also assigned TherapeuticsMD an industry rank of 94 out of 265 based on the ratings given to its competitors.

Several research analysts have recently weighed in on the stock. Noble Financial restated a “buy” rating and set a $17.50 price objective on shares of TherapeuticsMD in a research note on Monday, July 11th. Zacks Investment Research downgraded shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, August 10th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of TherapeuticsMD in a report on Wednesday, June 8th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/zacks-brokerages-set-15-63-target-price-for-therapeuticsmd-inc-nasdaqtxmd.html

TherapeuticsMD (NASDAQ:TXMD) traded down 0.15% during mid-day trading on Tuesday, hitting $6.66. 1,170,657 shares of the stock traded hands. The firm’s market cap is $1.31 billion. The firm’s 50-day moving average price is $7.09 and its 200-day moving average price is $7.67. TherapeuticsMD has a 52 week low of $5.18 and a 52 week high of $11.26.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The firm had revenue of $4.40 million for the quarter, compared to the consensus estimate of $5.63 million. TherapeuticsMD’s revenue was down 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.16) EPS. On average, equities analysts forecast that TherapeuticsMD will post ($0.43) earnings per share for the current fiscal year.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.